Drugs / IDP-023
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06677710 | Jun → Dec 2026 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Indapta Therapeutics, INC. | Suspended | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06119685 | Oct 2023 → Dec 2025 overdue | non-Hodgkin lymphoma, plasma cell myeloma | Indapta Therapeutics, INC. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDP-023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06677710 ↗ |
| Action | Deplete | “These cells may be particularly effective at targeting and killing the cells that cause the immune system to attack the nervous system in multiple sclerosis (MS).” NCT06677710 ↗ |
| Modality | Cell therapy | “off-the-shelf, allogeneic cell product made of "natural killer" cells, also called NK cells” NCT06119685 ↗ |